Monday, April 13, 2026 – MONDAY, April 13, 2026 — Your genetics might play a role in how well cutting-edge weight loss drugs like Ozempic and Zepbound will work for you, a new study says.Specific genetic traits can affect both weight loss and side effects for people taking…

Monday, April 13, 2026 – Amazon will offer the new GLP-1 pill, Foundayo, via kiosks and same-day delivery. Image credit: Michael Nagle/Bloomberg via Getty Images

Eli Lilly has announced the availability of the new GLP-1 pill, Foundayo, through Amazon One Medical kiosks. 

The new Amazon offering features same-day prescriptions after speaking with a healthcare professional. 

Foundayo is available through Amazon for $149 per month for the lowest dose.

Amazon One Medical kiosks have been stocking Novo Nordisk’s Wegovy pills since January. 

The Food and Drug Administration (FDA) recently approved Foundayo, Eli Lilly’s new GLP-1 pill for weight loss. 

Foundayo is available through the LillyDirect program and through Amazon Pharmacy, which fulfills prescriptions made through LillyDirect. 

Now, Amazon One Medical kiosks will offer Foundayo, which allows individuals to access their prescriptions on the same day after speaking with a healthcare professional. 

Amazon Pharmacy has offered home delivery of GLP-1 medications since 2021, but hasn’t been able to stock them in kiosks because they require refrigeration. 

GLP-1 pills, however, do not require cold storage, allowing for “broader access and for them to be ​stored safely in a kiosk for dispensing,” Tanvi Patel, a vice president at Amazon Pharmacy, ​said in a press release. 

Amazon Pharmacy kiosks have also been stocking the Wegovy pills since January. 

GLP-1 Amazon kiosks currently limited to California

Amazon announced its kiosks connected to One Medical locations in 2025.

There are currently five kiosks available in California. Amazon noted that the kiosks were developed to help reduce barriers to medication access and limit delivery fees. 

One Medical is Amazon’s primary and urgent care business. People can purchase a one-year subscription to One Medical for $199 or $99 with Amazon Prime. 

Those without a One Medical membership can still book an appointment and use the kiosks. 

Currently, Amazon kiosks are only available in certain areas of California. However, Hannah McClellan Richards, a vice president at Amazon Pharmacy, said in a press release that “the company plans to expand the kiosk model outside of California in 2026 and is in talks with external health systems to introduce the machines through partnerships.”

Same-day delivery available through WW

Individuals can also access Amazon’s same-day delivery for Foundayo through Lilly’s prescribing partners, such as WW International (formerly Weight Watchers). 

Some people may also have access to same-day delivery directly through Amazon.

Amazon hopes to expand same-day delivery to 4,500 locations by the end of this year. 

WW International and GoodRx have also said they will separately begin offering Foundayo at self-pay prices, starting at $149 per month for the lowest dose. 

What is the Foundayo pill? 

The Foundayo pill is the second GLP-1 medication to be approved in pill form.

For people with commercial insurance, it may cost as little as $25 per month. Individuals with Medicare Part D may be able to get Foundayo for $50 a month, beginning in July. 

“It is great to have new tools added to our toolbox to deal with obesity,” Zhaoping Li, MD, the chief of the Division of Clinical Nutrition at UCLA Health and director of the UCLA Center for Human Nutrition in Los Angeles, told Healthline in an earlier interview.

The starting dose for Foundayo is 0.8 milligrams (mg), increasing to 2.5 mg after 30 days, and then to 5.5 mg after a further 30 days. The dosage may be increased to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each level, based on a person’s response and tolerance to each dose. 

“Preferences vary by patient,” Mir Ali, MD, a bariatric surgeon and the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, told Healthine in an earlier interview.

“Some prefer weekly injections while others prefer a [daily] pill. A primary advantage of the pill is that it does not require refrigeration, making it more convenient for travel,” he said.

If you think you may be eligible for Foundayo or another GLP-1 medication, ask your doctor for more guidance.

Monday, April 13, 2026 – A newly discovered molecule could reshape the future of weight loss treatments by mimicking the powerful appetite-suppressing effects of drugs like Ozempic — but without many of the unpleasant side effects. Identified using artificial intelligence, this tiny peptide, called BRP, appears to act directly on the brain’s appetite-control center, helping animals eat less and lose fat without nausea or muscle loss.

Sunday, April 12, 2026 – A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.

Saturday, April 11, 2026 – Saturday, April 11 – More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

Friday, April 10, 2026 – Saturday, April 11 – (MedPage Today) — GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested.
Using U.S. electronic health record data, the incidence of…

Friday, April 10, 2026 – Saturday, April 11 – Here’s everything we know so far.

Friday, April 10, 2026 – Saturday, April 11 – New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the liver. Vivatides’ investors include …

Friday, April 10, 2026 – Friday, April 10 – By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.

Friday, April 10, 2026 – Friday, April 10 – → A decorated GLP-1 pioneer is retiring at Novo Nordisk.

Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the …

Friday, April 10, 2026 – Friday, April 10 – Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.

Thursday, April 9, 2026 – Friday, April 10 – Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

Thursday, April 9, 2026 – Friday, April 10 – (MedPage Today) — Integrating the most effective obesity treatments into cancer survivorship offers “an unprecedented opportunity” to improve long-term outcomes in cancer, including survival, a trio of obesity and oncology specialists argued in…

Thursday, April 9, 2026 – Friday, April 10 – The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout

Thursday, April 9, 2026 – Friday, April 10 – Steve Ubl, chief executive of PhRMA, plans to step down at the end of the ‌year, after more than a decade leading the main trade group for brand-name drug makers

Wednesday, April 8, 2026 – Thursday, April 9 – 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 receptor agonists, including semaglutide and tirzepatide, have transformed the clinical management of weight and obesity. However, patients experience substantial variability in both weight loss efficacy and the incidence of side effects. Some individuals lose less than 5% of their body weight, whereas others lose more than 20%. Some individuals experience side effects such as nausea and vomiting, whereas others do not.

Wednesday, April 8, 2026 – Thursday, April 9 – Changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs — and whether the drugs will cause nausea or vomiting.

Wednesday, April 8, 2026 – Thursday, April 9 –

Tuesday, April 7, 2026 – Wednesday April 8 – (MedPage Today) — In a whistleblower lawsuit, a prominent cardiologist says he was fired from the University of Pittsburgh Medical Center (UPMC) after reporting racist text messages exchanged between colleagues and a potential conflict of interest…

Tuesday, April 7, 2026 – Wednesday April 8 – (MedPage Today) — Novo Nordisk said its semaglutide (Wegovy) pill outperformed recently approved orforglipron (Foundayo) in weight loss and tolerability in an indirect comparison using clinical trial data, and the company launched multi-month…

Tuesday, April 7, 2026 – Wednesday April 8 – Plus, news about Vertex and Halozyme, Werewolf, and Regeneron:

Novo Nordisk launches high-dose Wegovy in the US: The 7.2 mg injectable form of the GLP-1 agonist is now available in the US to treat obesity …

Tuesday, April 7, 2026 – Wednesday April 8 – Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout

Tuesday, April 7, 2026 – Wednesday April 8 – The FDA has approved a new once-daily GLP-1 pill for weight loss. Image Credit: Healthline/Photo by Eli Lilly

Federal regulators have approved the GLP-1 tablet Foundayo for use in weight management.

Experts say having another weight loss medication in pill form could help people stick to a weight management regimen.

Monday, April 6, 2026 – MONDAY, April 6, 2026 — Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the…

Monday, April 6, 2026 – Tuesday, April 7 – Combat muscle loss with this 7-move routine.

Monday, April 6, 2026 – Tuesday, April 7 – Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Monday, April 6, 2026 – Tuesday, April 7 – Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to safety concerns regarding the use of this GLP medication, alongside a mix of potential benefits.

Saturday, April 4, 2026 – Sunday, April 5 – (MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical…

Thursday, April 2, 2026 – Friday, April 3 – PLAINSBORO, NJ and BAGSVÆRD, Denmark, April 2, 2026 /PRNewswire/ — Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25…

Thursday, April 2, 2026 – Friday, April 3 – Their effectiveness also depends on what else you do when you take them.

Thursday, April 2, 2026 – THURSDAY, April 2, 2026 — A popular weight loss drug may soon be more affordable for some people.
Danish pharmaceutical company Novo Nordisk has launched a subscription program for its obesity treatment Wegovy, offering lower and more…

Thursday, April 2, 2026 – THURSDAY, April 2, 2026 — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in the April issue of Plastic and…

Thursday, April 2, 2026 – Friday, April 3 – A day after Eli Lilly gained FDA approval for its obesity pill Foundayo, Novo Nordisk is fighting back with an analysis that it says shows the superiority of its own oral drug.

…

Thursday, April 2, 2026 – Friday, April 3 – (MedPage Today) — As a primary care physician and obesity board-certified specialist, I believe that GLP-1s are one of the best medical interventions of all time, right up there with vaccines, antibiotics, blood thinners, and statins. They really…

Thursday, April 2, 2026 – Friday, April 3 – Potential import tariffs on drugs, Foundayo is here-o, and other biotech news from The Readout

Wednesday, April 1, 2026 – Thursday, April 2 – Eli Lilly and Co. anticipates shipping newly approved Foundayo (orforglipron) within the next week, as the drug becomes the second oral weight-loss glucagon-like peptide-1 (GLP-1) receptor agonist to enter the U.S. market following December’s approval of Novo Nordisk A/S’ Wegovy (semaglutide) pill.

Wednesday, April 1, 2026 – Thursday, April 2 – Wegovy (semaglutide) has passed the notoriously strict cost-effectiveness scrutiny of the U.K. health technology assessment body and will now be reimbursed for the prevention of further serious cardiovascular events in people who have had a heart attack or stroke, or are diagnosed with peripheral arterial disease.

Wednesday, April 1, 2026 – Thursday, April 2 – Physical activity is crucial when you’re taking this medication.

Wednesday, April 1, 2026 – Thursday, April 2 – (MedPage Today) — The FDA has approved a second oral GLP-1 receptor agonist for weight loss in adults with obesity or overweight and weight-related comorbidities.
A once-daily tablet, orforglipron (Foundayo) is indicated in conjunction with a…

Wednesday, April 1, 2026 – Thursday, April 2 – Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.